News

In connection with the financing, the company issued to the investors convertible promissory notes in the aggregate principal amount of $3.24 million and warrants to purchase an aggregate

Teva has completed enrollment for the first of its two Phase III clinical trials for laquinimod (Allegro) in November 2008 and is currently enrolling relapsing-remitting multiple sclerosis (RRMS)

According to the company, the Smartfil system is the first powered device approved to be used with dermal fillers and the first product in the new category of

Mr Barnavon is senior vice president with Clarity Partners. Mr Barnavon’s appointment fills the vacancy created from the resignation of Kevin Lu from the board of directors. As

The animal-model study demonstrated a marked suppression of a microRNA that was found to be over expressed in human hepato-cellular carcinoma (HCC), and a significant two-fold reduction of

Other participating investors include RiverVest Venture Partners, as well as existing investors SV Life Sciences, HBM BioVentures, Aberdare Ventures and Adams Street Partners. These investors have made commitments

Total revenue for the three months ended December 31, 2008 was $7.3 million, a 74% increase, compared to $4.2 million in the same period of 2007. Total revenue

Dr Grynspan will report directly to Zami Aberman, chairman, president and CEO of Pluristem. Prior to joining Pluristem, Dr Grynspan served as vice president of R&D of a

According to the company, employees directly affected by the restructuring plan will receive severance payments, continuation of benefits and outplacement assistance. The company estimates incurring personnel-related restructuring charges